Amgen eyes potential acquisitions
Executive Summary
Amgen's consolidation of Immunex gives the company confidence that it could pursue other large agreements, CEO Sharer said Feb. 25, but "that doesn't mean we're just going to [do] it for the heck of it." While "acquisitions are something that we don't expect," Sharer says, "obviously, given that prices are much lower right now, we're looking harder." The CEO outlined Amgen's criteria for a takeover prospect, which include an ability to drive top-line growth and a fit with Amgen's culture...
You may also be interested in...
Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Building Trust In Brands Should Be A Continuous Process For The Self-Care Industry
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
Diversified Sourcing And Sustainability Are Key For Centrient
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: